Veterinary Services MarketSize, Share & Industry Analysis, 2026-2034By Animal TypeBy Service TypeBy Delivery ChannelBy Practice OwnershipBy Payment Mode
Full title & scope — all 5 axes with their segments
Veterinary Services Market Size, Share & Industry Analysis, By Animal Type (Companion Animal, Production Animal, Others), By Service Type (Physical health monitoring, Diagnostic tests and imaging, Surgery, Others), By Delivery Channel (Hospitals and Clinics, Commercial Facilities, Outdoors/Ambulatory, Others), By Practice Ownership (Independent Practices, Corporate/Chain-Owned Practices), By Payment Mode (Out-of-Pocket, Insurance-Covered), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By Animal TypeCompanion Animal · Production Animal · Others
- 02By Service TypePhysical health monitoring · Diagnostic tests and imaging · Surgery
- 03By Delivery ChannelHospitals and Clinics · Commercial Facilities · Outdoors/Ambulatory
- 04By Practice OwnershipIndependent Practices · Corporate/Chain-Owned Practices
- 05By Payment ModeOut-of-Pocket · Insurance-Covered
- 06By Region
Market Analysis & Outlook
Veterinary services cover the diagnostic, preventive, medical and surgical care that a licensed practice or mobile provider delivers to companion and production animals, spanning routine wellness exams, vaccination and parasite control, diagnostic imaging and laboratory testing, and surgical or emergency treatment. Buyers range from individual pet owners and breeders to commercial livestock operations, dairies and poultry integrators that contract ongoing herd or flock health management. Care is delivered through fixed hospitals and clinics, retail or commercial facilities, and outdoor or ambulatory visits where a provider travels to the animal instead of the animal being brought in.
Between 2025 and 2034 the global veterinary services market moves from USD 131.43 billion to USD 291.71 billion, compounding at 9.35% a year. Fifteen years are covered in all, taking in USD 91.55 billion in 2020, USD 122.26 billion in 2024, USD 142.73 billion in 2026 and USD 206.65 billion in 2030.
57% of 2025 revenue sits in Companion Animal, worth USD 74.92 billion and rising to USD 180.86 billion at 62% by 2034, the largest animal type line in both years. Growth is fastest in Companion Animal at 10.37% and slowest in Production Animal at 7.58%. The lines gaining share are Companion Animal. Production Animal and Others lose share without losing revenue.
The service type split puts Physical health monitoring first, at USD 49.94 billion and 38% of revenue in 2025, rising to USD 99.18 billion and 34% in 2034. Diagnostic tests and imaging grows faster at 11.65% against 7.91%, moving from 28% of revenue to 34% by 2034. It cuts the same total as the animal type axis from a different commercial angle, so revenue does not add across the two.
USD 44.69 billion of 2025 revenue is generated in North America, 34% of the global total and the largest regional share; it reaches USD 87.51 billion by 2034. Europe is next at 26% and USD 34.17 billion, and Middle East and Africa last at 7%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates instead of spreading across all five regions.
Behind these figures sit five regions, three animal type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global veterinary services market moves from USD 91.55 billion in 2020 to USD 131.43 billion in 2025 and USD 291.71 billion by 2034, the forecast period compounding at 9.35% a year.
- The largest line by animal type is Companion Animal, worth USD 74.92 billion and 57% of revenue in 2025, rising to USD 180.86 billion and 62% by 2034.
- The bull case puts 2034 revenue at USD 309.21 billion and the bear case at USD 271.29 billion, either side of the USD 291.71 billion base case, each with its own stated assumption in the full report.
- The largest region is North America, generating USD 44.69 billion in 2025 (34% of the global total) and USD 87.51 billion by 2034, ahead of Europe at 26%.
- The United States accounts for 85% of North America in the base year, worth USD 37.99 billion in 2025 and reaching USD 74.38 billion by 2034, the worked country example carried through that region's chapters.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By by animal type
Base year 2025Companion Animal leads with 57.0% of by animal type segment revenue.
Share of by animal type segment revenue, most recent base year.
The global veterinary services market is shaped over 2026-2034 by three measurable movements: a change in the animal type mix, a shift in where revenue sits geographically, and the 9.35% rate carrying the total.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Companion Animal outpaces Production Animal. Between 2026 and 2034, 10.37% growth in Companion Animal against 7.58% in Production Animal pulls the animal type mix apart. Over the forecast period that moves Companion Animal from 57% of revenue to 62%, and Production Animal from 37% to 32%. Revenue rises on both sides; USD 74.92 billion to USD 180.86 billion and USD 48.63 billion to USD 93.35 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 24% of revenue in 2025 to 30% in 2034, worth USD 31.54 billion rising to USD 87.51 billion; Latin America moves from 9% of revenue in 2025 to 9.5% in 2034, worth USD 11.83 billion rising to USD 27.71 billion; Middle East and Africa moves from 7% of revenue in 2025 to 7.5% in 2034, worth USD 9.2 billion rising to USD 21.88 billion. Against that, North America at 34% moving to 30%, Europe at 26% moving to 23%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
The series never breaks trajectory. Year by year the total runs USD 91.55 billion in 2020, USD 122.26 billion in 2024, USD 131.43 billion in 2025, USD 142.73 billion in 2026, USD 206.65 billion in 2030 and USD 291.71 billion in 2034. No year breaks the trajectory, and the 9.35% forecast rate compares with 7.51% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the animal type and regional axes, not by the headline rate.
Market Growth Factors
Companion Animal carries the market's growth rate
Market Drivers
3- 01Companion Animal carries the market's growth rate
The fastest line on the animal type axis is Companion Animal, at 10.37% against the market's 9.35%, taking USD 74.92 billion to USD 180.86 billion and 57% of revenue to 62%. Because the spread to Production Animal at 7.58% is this wide, the headline 9.35% is a weighted result, not a rate any single line achieves. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02Regional weight, not regional count
The largest regional base is North America: USD 44.69 billion in 2025 at 34% of the global total, USD 87.51 billion by 2034, still 30%. Behind it, Europe holds 26%; USD 34.17 billion rising to USD 67.09 billion. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03A demonstrated trajectory, not a projected turnaround
USD 91.55 billion in 2020, USD 122.26 billion in 2024 and USD 131.43 billion in 2025: 7.51% compound growth before the forecast period even begins. From there the forecast carries 9.35% through to USD 291.71 billion in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 9.35% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising companion animal ownership and premiumization of pet care | High | +58 | High | High | High |
| 2 | Expansion of pet insurance penetration | Medium-High | +28 | Medium | High | High |
| 3 | Corporate consolidation and chain expansion of veterinary practices | Medium-High | +24 | High | Medium | Medium |
| 4 | Growth in livestock production and food-animal health spending in emerging markets | Medium | +22 | Medium | Medium | Medium |
| 5 | Adoption of in-house diagnostic imaging and point-of-care testing | Medium | +18 | Medium | Medium | High |
| 6 | Others | Medium | +39.28 | Low | Medium | Medium |
| Total | +189.28 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Shortage of licensed veterinary professionals constraining service capacity | Medium-High | −14 | High | Medium | Medium |
| 2 | Rising cost of veterinary care limiting utilization among price-sensitive owners | Medium | −9 | Medium | Medium | Medium |
| 3 | Regulatory and biosecurity constraints on cross-border livestock veterinary services | Low | −6 | Low | Low | Medium |
| Total | −29 | |||||
Drivers contribute 189.28 Billion and restraints remove 29 Billion, a net 160.28 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 9.35% into its parts and three show up: an already-large base compounding, the animal type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 271.29 billion by 2034, against USD 291.71 billion in the base case
Market Restraints
2- 01Downside case: USD 271.29 billion by 2034, against USD 291.71 billion in the base case
The study's downside path assumes the bear case assumes a slower pace of veterinary licensing capacity expansion and softer discretionary pet care spending in a weaker consumer environment, holding visit growth and pricing below the base case, and ends 2034 at USD 271.29 billion against the USD 291.71 billion base case, the same USD 131.43 billion base year, a slower forecast period.
- 02Production Animal holds the blended rate down
With 37% of 2025 revenue (USD 48.63 billion) Production Animal is where most of the market sits, and it grows at only 7.58% against the market's 9.35%. Revenue still reaches USD 93.35 billion by 2034 and share still falls to 32%: a drag on the average, not a decline.
Market Opportunities
Upside case: USD 309.21 billion by 2034
Market Opportunities
2- 01Upside case: USD 309.21 billion by 2034
The bull case assumes pet insurance adoption and corporate practice consolidation both proceed faster than the base case, lifting visit frequency and average revenue per visit across the forecast. On that assumption the market reaches USD 309.21 billion by 2034 against USD 291.71 billion in the base case, from the same USD 131.43 billion in 2025.
- 02Companion Animal share moves from 57% to 62%
Share on the animal type axis moves toward Companion Animal, from 57% in 2025 to 62% in 2034, on 10.37% growth against the market's 9.35% and revenue rising from USD 74.92 billion to USD 180.86 billion. Taking position there does not require displacing whoever holds Companion Animal, which is the harder and more expensive fight.
Market Challenges
Concentration on the animal type axis
Market Challenges
2- 01Concentration on the animal type axis
One line dominates: Companion Animal, at 57% of revenue in 2025 and 62% in 2034, worth USD 74.92 billion and USD 180.86 billion. A market leaning this heavily on one animal type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02North America is largely the United States
North America is worth USD 44.69 billion in 2025 and USD 37.99 billion of that is the United States; 85% of the region, reaching USD 74.38 billion in 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
5 axesThe market is divided by animal type and by service type, delivery channel, practice ownership and payment mode; five axes in all. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market, not additions to it.
Three animal type lines are reported. One of them takes share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Animal Type · 3 segments
Companion Animal Both Leads the Animal type Axis and Grows Fastest on It
- Largest Companion Animal · 57%
- Fastest Companion Animal · 10.4%
- Moves most Companion Animal · +5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Companion Animal | $74.92B | 57% | $181B | 62%+5 | 10.4% |
| Production Animal | $48.63B | 37% | $93.35B | 32%-5 | 7.6% |
| Others | $7.89B | 6% | $17.50B | 6% | 9.3% |
Companion animal care leads because pet ownership has broadened across urban households and owners increasingly treat routine and preventive visits as a recurring commitment, not an occasional expense. The same segment grows fastest as insurance coverage lowers the cost barrier to advanced treatment and diagnostic work, while production animal demand tracks livestock output more closely and expands at a steadier, population-linked pace. By 2034 Companion Animal is still ahead, making this a shift in weight, not a change of leader. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Service Type · 4 segments
Physical health monitoring Led by Service type in 2025, with Diagnostic tests and imaging Growing Fastest
- Largest Physical health monitoring · 38%
- Fastest Diagnostic tests and imaging · 11.7%
- Moves most Diagnostic tests and imaging · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Physical health monitoring | $49.94B | 38% | $99.18B | 34%-4 | 7.9% |
| Diagnostic tests and imaging | $36.80B | 28% | $99.18B | 34%+6 | 11.7% |
| Surgery | $31.54B | 24% | $67.09B | 23%-1 | 8.8% |
| Others | $13.14B | 10% | $26.25B | 9%-1 | 8% |
Physical health monitoring leads because routine wellness visits recur far more often than any single surgical or diagnostic episode, giving it a broad and dependable base. Diagnostic tests and imaging grow fastest as clinics add in-house bloodwork, ultrasound and radiography capacity that previously required referral, shortening the path from symptom to treatment and encouraging owners to test early instead of waiting. The order does not change: Physical health monitoring is still largest in 2034, and what moves is how much it holds.
By Delivery Channel · 4 segments
Scale in Hospitals and Clinics and Growth in Outdoors/Ambulatory Define the Delivery channel Axis
- Largest Hospitals and Clinics · 62%
- Fastest Outdoors/Ambulatory · 11.7%
- Moves most Hospitals and Clinics · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals and Clinics | $81.49B | 62% | $169B | 58%-4 | 8.5% |
| Commercial Facilities | $23.66B | 18% | $55.42B | 19%+1 | 9.9% |
| Outdoors/Ambulatory | $18.40B | 14% | $49.59B | 17%+3 | 11.7% |
| Others | $7.89B | 6% | $17.50B | 6% | 9.3% |
Hospitals and clinics remain the leading channel because they concentrate the equipment, staff and continuity of care that both companion and production animal owners rely on for anything beyond routine attention. Outdoors and ambulatory services grow fastest as mobile practices and farm-call models extend coverage into rural and peri-urban areas where a fixed clinic is not economically viable. Hospitals and Clinics remains the largest line through 2034, so the axis changes in proportion, not in order.
By Practice Ownership · 2 segments
Corporate/Chain-Owned Practices Outpaces the Axis While Independent Practices Holds the Largest Share
- Largest Independent Practices · 64%
- Fastest Corporate/Chain-Owned Practices · 12.8%
- Moves most Independent Practices · -12 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Independent Practices | $84.12B | 64% | $152B | 52%-12 | 6.8% |
| Corporate/Chain-Owned Practices | $47.31B | 36% | $140B | 48%+12 | 12.8% |
Independent practices still hold the larger share because most veterinary care is delivered through small, locally owned clinics built on long-standing client relationships. Corporate and chain-owned practices grow fastest as consolidators acquire independent sites to gain purchasing scale, standardize clinical protocols and fund the equipment upgrades that a single-location practice would find harder to finance alone. The order does not change: Independent Practices is still largest in 2034, and what moves is how much it holds.
By Payment Mode · 2 segments
Insurance-Covered Outpaces the Axis While Out-of-Pocket Holds the Largest Share
- Largest Out-of-Pocket · 82%
- Fastest Insurance-Covered · 14.3%
- Moves most Out-of-Pocket · -9 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Out-of-Pocket | $108B | 82% | $213B | 73%-9 | 7.9% |
| Insurance-Covered | $23.66B | 18% | $78.76B | 27%+9 | 14.3% |
Out-of-pocket payment leads because pet insurance and livestock indemnity products remain unevenly adopted across regions and most owners still settle the bill directly at the point of care. Insurance-covered spending grows fastest as insurers broaden policy availability and owners respond to rising treatment costs by shifting toward coverage that reduces the size of a single unplanned bill. The order does not change: Out-of-Pocket is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 4 points of share move elsewhere by 2034, while revenue still grows 2.0×.
- Rank 1 of 5
- 2025 share 34%
- By 2034 30%
- Revenue $44.69B → $87.51B
North America holds 34% of the global veterinary services market in 2025, worth USD 44.69 billion and reaches USD 87.51 billion by 2034. It is a leading region on this axis, first by revenue throughout the period.
By 2034 the share stands at 30%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
The animal type mix reported at global level applies here, with Companion Animal the largest line at 57% of 2025 revenue and Companion Animal the fastest-growing at 10.37%. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 85% of it, growing 2.0×.
- In region 1 of 2
- Of region 85%
- Of global 28.9%
- Revenue $37.99B → $74.38B
The largest single market in North America is the United States, at USD 37.99 billion in 2025 and USD 74.38 billion in 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 44.69 billion and USD 87.51 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
the United States buys along the same lines as the market globally; Companion Animal first at 57% of 2025 revenue and 62% in 2034, Companion Animal fastest at 10.37% on a share moving from 57% to 62%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The United States carries its own animal type breakdown in the full report.
In the United States, the practice of veterinary medicine is licensed and disciplined at the state level under each state's veterinary practice act, administered by a state veterinary medical board that examines candidates, issues licenses to veterinarians and credentialed veterinary technicians, and sets standards of care and continuing education. Veterinary colleges are accredited through the American Veterinary Medical Association's Council on Education, and hospitals may seek voluntary facility accreditation through bodies such as the American Animal Hospital Association. Drugs, biologics, and devices used in delivering these services fall under the Food and Drug Administration's Center for Veterinary Medicine and the Department of Agriculture, so a provider's supply chain answers to federal rules even though the license to practice remains a state matter.
In the United States the field is Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. The full report covers country-level positioning and shares company by company; this summary does not.
Canada
2nd-largest in North America, growing 2.0×.
- In region 2 of 2
- Of region 15%
- Of global 5.1%
- Revenue $6.70B → $13.13B
5.1% of global revenue is generated in Canada; USD 6.7 billion in 2025, reaching USD 13.13 billion in 2034, and 15% of North America.
Europe Market Analysis
The 2nd-largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 2.0×.
- Rank 2 of 5
- 2025 share 26%
- By 2034 23%
- Revenue $34.17B → $67.09B
26% of the global veterinary services market sits in Europe in 2025, worth USD 34.17 billion and reaches USD 67.09 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.
23% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The animal type mix reported at global level applies here, with Companion Animal the largest line at 57% of 2025 revenue and Companion Animal the fastest-growing at 10.37%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.
Germany
The largest market in Europe, growing 2.0×.
- In region 1 of 3
- Of region 27%
- Of global 7%
- Revenue $9.23B → $18.11B
27% of Europe's base-year revenue comes from Germany; USD 9.23 billion, rising to USD 18.11 billion by 2034. At 27% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Against regional totals of USD 34.17 billion in 2025 and USD 67.09 billion in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Companion Animal at 57% of 2025 revenue, easing to 62% by 2034, and the fastest is Companion Animal at 10.37%, from 57% to 62%. Its 27% weight in Europe means those movements carry straight into the regional totals. Revenue by animal type for Germany is reported separately in the full report.
Veterinary services in Germany operate under the Federal Veterinary Act, which requires practitioners to pass a state examination and register with the veterinary chamber of the federal state in which they practice; these chambers, coordinated nationally through the Bundestierärztekammer, set professional conduct rules and continuing education obligations. Animal health surveillance and disease control sit with the Friedrich-Loeffler-Institut and the federal and state agriculture ministries, while veterinary medicinal products used in clinics are governed by the German Medicines Act alongside the EU framework for veterinary medicines. A clinic or mobile practice must combine chamber registration for its veterinarians with compliance on the medicines it dispenses and administers.
The suppliers tracked in this study (Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL) compete in Germany across the animal type lines above. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. A supplier weighted toward Europe is competing over a base of USD 34.17 billion in 2025 reaching USD 67.09 billion by 2034, 26% of global revenue at the start of that period.
France
2nd-largest in Europe, growing 2.0×.
- In region 2 of 3
- Of region 20%
- Of global 5.2%
- Revenue $6.83B → $13.42B
5.2% of global revenue is generated in France; USD 6.83 billion in 2025, reaching USD 13.42 billion in 2034, and 20% of Europe.
United Kingdom
3rd-largest in Europe, growing 2.0×.
- In region 3 of 3
- Of region 19%
- Of global 4.9%
- Revenue $6.49B → $12.75B
4.94% of global revenue is generated in the United Kingdom; USD 6.49 billion in 2025, reaching USD 12.75 billion in 2034, and 19% of Europe.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 6 points of share by 2034, while revenue still grows 2.8×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 30%
- Revenue $31.54B → $87.51B
In Asia Pacific, 24% of global revenue puts 2025 at USD 31.54 billion with USD 87.51 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
Its share rises to 30% over the forecast period, on growth above the market's own 9.35%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Companion Animal leads here as it does globally, at 57% of 2025 revenue, and Companion Animal again grows fastest at 10.37%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.8×.
- In region 1 of 3
- Of region 32%
- Of global 7.7%
- Revenue $10.09B → $28B
32% of Asia Pacific's base-year revenue comes from China; USD 10.09 billion, rising to USD 28 billion by 2034. At 32% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 31.54 billion in 2025 and USD 87.51 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in China follows the animal type mix reported at global level: Companion Animal is the largest line at 57% of 2025 revenue, moving to 62% by 2034, while Companion Animal grows fastest at 10.37% and takes its share from 57% to 62%. Since 32% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. China carries its own animal type breakdown in the full report.
China's Ministry of Agriculture and Rural Affairs sets the national framework for veterinary practice under regulations governing veterinary practitioners, requiring individuals to pass a national qualification examination and register before treating animals or operating a clinic. Provincial and municipal agriculture bureaus license veterinary hospitals and clinics locally, inspect premises, and enforce hygiene and biosecurity requirements tied to the country's animal epidemic prevention rules. Veterinary drugs and biologics dispensed during treatment are separately controlled through the national veterinary drug administration system, with clinics expected to source only approved products and keep records supporting traceability back to a licensed supplier or manufacturer.
Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL are the suppliers covered in China. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. Weighting toward Asia Pacific means competing for 24% of 2025 global revenue, a base of USD 31.54 billion moving to USD 87.51 billion across the forecast period.
Japan
2nd-largest in Asia Pacific, growing 2.8×.
- In region 2 of 3
- Of region 20%
- Of global 4.8%
- Revenue $6.31B → $17.50B
Japan is sized at USD 6.31 billion in 2025, rising to USD 17.5 billion by 2034; 4.8% of global revenue and 20% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
India
3rd-largest in Asia Pacific, growing 2.8×.
- In region 3 of 3
- Of region 15%
- Of global 3.6%
- Revenue $4.73B → $13.13B
3.6% of global revenue is generated in India; USD 4.73 billion in 2025, reaching USD 13.13 billion in 2034, and 15% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.5 points of share by 2034, while revenue still grows 2.3×.
- Rank 4 of 5
- 2025 share 9%
- By 2034 9.5%
- Revenue $11.83B → $27.71B
USD 11.83 billion of 2025 revenue is generated in Latin America, 9% of the global veterinary services market with USD 27.71 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
Its share rises to 9.5% over the forecast period, so the region grows faster than the market's 9.35% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Companion Animal leads here as it does globally, at 57% of 2025 revenue, and Companion Animal again grows fastest at 10.37%. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 2.3×.
- In region 1 of 2
- Of region 45%
- Of global 4%
- Revenue $5.32B → $12.47B
USD 5.32 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 12.47 billion by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 11.83 billion in 2025 and USD 27.71 billion in 2034, it is the country the full report breaks out in detail.
The animal type pattern in Brazil is the global one: 57% of 2025 revenue in Companion Animal, 62% by 2034, against 10.37% growth in Companion Animal taking it from 57% to 62%. Because the country carries 45% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by animal type for Brazil is reported separately in the full report.
In Brazil, veterinary practice is licensed through the Federal Council of Veterinary Medicine and its regional councils, which register veterinarians, accredit veterinary establishments, and enforce a code of professional ethics covering clinical conduct and advertising. The Ministry of Agriculture, Livestock and Supply sets animal health policy and oversees the products and biologics used within clinical settings, working alongside state-level agricultural defense agencies on disease notification and control. A veterinary clinic or hospital must hold current registration with its regional council, employ only licensed veterinarians, and maintain facilities that meet the council's standards for hygiene, equipment, and record-keeping before it can lawfully treat animals or advertise its services.
The suppliers tracked in this study (Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL) compete in Brazil across the animal type lines above. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. The commercial size of that position is USD 11.83 billion in 2025 and USD 27.71 billion by 2034, 9% of the global total in the base year.
Mexico
2nd-largest in Latin America, growing 2.3×.
- In region 2 of 2
- Of region 25%
- Of global 2.3%
- Revenue $2.96B → $6.93B
2.25% of global revenue is generated in Mexico; USD 2.96 billion in 2025, reaching USD 6.93 billion in 2034, and 25% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.5 points of share by 2034, while revenue still grows 2.4×.
- Rank 5 of 5
- 2025 share 7%
- By 2034 7.5%
- Revenue $9.20B → $21.88B
USD 9.2 billion of 2025 revenue is generated in Middle East and Africa, 7% of the global veterinary services market and reaches USD 21.88 billion by 2034. Among the five regions it ranks fifth by revenue in both years.
By 2034 the share has moved up to 7.5%, so the region grows faster than the market's 9.35% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Segment composition follows the global pattern: Companion Animal largest at 57% of 2025 revenue, Companion Animal fastest at 10.37%. Per-axis and per-country detail for Middle East and Africa sits in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.4×.
- In region 1 of 2
- Of region 22%
- Of global 1.5%
- Revenue $2.02B → $4.81B
USD 2.02 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 4.81 billion by 2034. At 22% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. The region itself runs USD 9.2 billion to USD 21.88 billion over the same period, and this is the market carrying the country-level detail in the full report.
Saudi Arabia buys along the same lines as the market globally; Companion Animal first at 57% of 2025 revenue and 62% in 2034, Companion Animal fastest at 10.37% on a share moving from 57% to 62%. Because the country carries 22% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-animal type revenue for Saudi Arabia appears on its own in the full report.
Veterinary services in Saudi Arabia fall under the Ministry of Environment, Water and Agriculture, which licenses veterinarians and veterinary clinics, sets facility standards, and coordinates animal health and disease control programs nationally. The Saudi Food and Drug Authority separately governs the veterinary medicines and biologics that a clinic dispenses or administers, requiring registration of products before they reach clinical use. A provider seeking to open a clinic or hospital must obtain ministry approval for the premises and staff qualifications in addition to complying with product-level registration, so licensure runs on two parallel tracks: one for the premises and staff, another for each product placed into clinical use.
The suppliers tracked in this study (Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL) compete in Saudi Arabia across the animal type lines above. One line leads on both counts here: Companion Animal holds 57% of 2025 revenue and compounds fastest at 10.37%. A supplier weighted toward Middle East and Africa is competing over a base of USD 9.2 billion in 2025 reaching USD 21.88 billion by 2034, 7% of global revenue at the start of that period.
South Africa
2nd-largest in Middle East and Africa, growing 2.4×.
- In region 2 of 2
- Of region 20%
- Of global 1.4%
- Revenue $1.84B → $4.38B
Within Middle East and Africa, South Africa accounts for 20% of regional revenue and 1.4% of the global total, worth USD 1.84 billion in 2025 and USD 4.38 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by animal type, service type, delivery channel, practice ownership, payment mode, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Animal type Axis Decides Competitive Standing
The study covers the following suppliers: Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL.
The competitive line that matters is the animal type one, not the geographic one. 57% of 2025 revenue, worth USD 74.92 billion, is in Companion Animal, still 62% of the total in 2034; that is the position least likely to change hands. Share moves in Companion Animal, growing 10.37% against 7.58% for Production Animal. Holding the first and taking the second are separate capabilities, which is why a market of USD 131.43 billion supports as many suppliers as it does.
What separates suppliers in this market is less the treatment itself than the ability to get a validated product or protocol into a clinic or farm reliably and keep it there. The largest players hold the deepest veterinary regulatory approval portfolios across species and geographies, manufacturing scale that keeps vaccine and pharmaceutical supply steady through demand spikes, and distribution relationships that reach both companion animal clinics and large-scale livestock operations. Smaller and regional suppliers compete on specialization: a narrower disease or species focus, closer relationships with local veterinary networks, and faster registration in markets where a global player's approval queue moves slowly.
Geographic reach is the other axis of competition. North America alone accounts for 34% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 26%.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Veterinary Services Market Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Merck Animal Health(United States)
- Ceva Sante Animale(France)
- Vetoquinol S.A.(France)
- Zoetis(United States)
- Boehringer Ingelheim GmbH(Germany)
- Elanco(United States)
- Nutreco N.V.(Netherlands)
- Virbac(France)
- Kindred Biosciences, Inc.(United States)
- Biogenesis Bago(Argentina)
- Indian Immunologicals Ltd.(India)
- Neogen Corp.(United States)
- Hester Biosciences(India)
- Phibro Animal Health(United States)
- Dechra Pharmaceuticals PL
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Animal Type, Service Type, Delivery Channel, Practice Ownership, Payment Mode), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Veterinary Services Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Veterinary Services Market Overview, By Animal Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Veterinary Services Market Overview, By Service Type, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Veterinary Services Market Overview, By Delivery Channel, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Veterinary Services Market Overview, By Practice Ownership, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Veterinary Services Market Overview, By Payment Mode, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Veterinary Services Market Size — Segment Comparison
Chapter 22.Global Veterinary Services Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Veterinary Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Veterinary Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Veterinary Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Veterinary Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Veterinary Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Animal Type
3- 01Companion Animal
- 02Production Animal
- 03Others
By Service Type
4- 01Physical health monitoring
- 02Diagnostic tests and imaging
- 03Surgery
- 04Others
By Delivery Channel
4- 01Hospitals and Clinics
- 02Commercial Facilities
- 03Outdoors/Ambulatory
- 04Others
By Practice Ownership
2- 01Independent Practices
- 02Corporate/Chain-Owned Practices
By Payment Mode
2- 01Out-of-Pocket
- 02Insurance-Covered
Segment categories shown for scope reference. See the Summary tab for revenue share by By Animal Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from the number of veterinary visits and procedures performed each year across companion and production animal caseloads, multiplied by the realized revenue per visit or per head for consultation, diagnostic, surgical and preventive care lines separately. Visit volumes are anchored to animal population counts and clinic density by region, and average revenue per visit is set from disclosed pricing and reimbursement data where it exists. This bottom-up build is then checked against the animal health and diagnostics revenue that companies such as Zoetis, Elanco and Boehringer Ingelheim disclose for their veterinary-facing businesses; where the two diverge, the visit-volume or price-per-visit assumption is revisited instead of the company figures themselves.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targets practice owners and clinic managers who set visit pricing and service mix, procurement and integration leads at corporate practice groups who can speak to consolidation economics, distributors and wholesalers who move pharmaceuticals and diagnostic consumables into clinics and farms, and veterinary licensing and regulatory contacts who track practitioner supply and registration activity. Sampling weights North America and Europe, where corporate consolidation and pet insurance adoption are furthest along and disclosure is richest, while adding enough coverage in Asia Pacific and Latin America to capture livestock-driven demand that the mature markets do not represent.
Desk research draws on national veterinary licensing board registers for practitioner counts, FAO and national agriculture ministry livestock population statistics, and customs trade data filed under the HS codes covering veterinary pharmaceuticals and vaccines to track cross-border supply. Company filings from publicly listed animal health suppliers, including Zoetis, Elanco and Dechra, provide disclosed segment revenue for cross-checking. Pet insurance association penetration data and national veterinary association benchmark surveys fill in payment-mode and practice-economics detail that trade data alone does not capture.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast carries forward the pet ownership and insurance-adoption curves observed in the historical period, tempering the adoption surge recorded during 2020 and 2021 that will not repeat at the same pace. Corporate consolidation is modeled as a gradual share shift from independent to chain-owned practices, not a fixed annual rate, since acquisition activity varies with financing conditions. Livestock-side demand is tied to production volume growth in the countries covered, not to companion animal trends. The forecast holds only if veterinary licensing capacity expands broadly in line with recent trends and no major disease outbreak forces a step change in demand.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested against the 2020-2024 historical growth actually implied by the model, confirming the build reproduces the recorded expansion in visit volume and pricing before being extended into the forecast. Segment-level shifts, particularly the pace of insurance-covered payment and corporate practice ownership, were reviewed against the pattern already visible in the historical years, not assumed to continue unchanged. Sensitivities were tested on the insurance-adoption rate, the corporate consolidation pace, and livestock production growth in the largest production animal markets, since each carries enough uncertainty to move the 2034 total by more than a marginal amount.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest for companion animal care and delivery-channel splits in North America and Europe, where clinic pricing and corporate consolidation activity are disclosed with reasonable regularity. It is weaker for production animal spending in Latin America, the Middle East and Africa, and for payment-mode splits outside markets with mature pet insurance industries, where reporting is thin and often inferred from adjacent livestock or agriculture data. A widespread disease outbreak, a sudden shift in veterinary licensing capacity, or a sharp change in livestock trade policy would be the most likely causes of a material revision to this estimate.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Veterinary Services Market projected to reach?
USD 291.71 Billion by 2034, CAGR 9.35%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 34% of global revenue through 2034.
05Which segment leads the market?
Companion Animal is the largest line by animal type, at 57% of revenue in 2025.
06Who are the key companies profiled?
Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health, Dechra Pharmaceuticals PL. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.